Royalty Pharma Plc (RPRX)
Royalty Pharma plc is a healthcare company listed on NASDAQ under the ticker RPRX. It focuses on buying biopharmaceutical royalties and providing funding for innovation in the biopharmaceutical sector in the United States. The company’s portfolio includes royalties linked to about 35 marketed therapies and around 20 development-stage product candidates across areas such as rare disease, oncology, neuroscience, infectious disease, hematology, and diabetes. Founded in 1996 and based in New York, New York, Royalty Pharma operates within the pharmaceuticals industry as an issuer of common stock.
Stock Summary
Fair Value
Profitability & Growth
Quality & Risk
Events & Dividends
Technical Outlook
FAQ
Jump between the core stock analysis sections, valuation data, fair value models, technical outlook, and FAQ.
Data update note:
Fair value and stock analysis metrics are updated after regular market sessions when new data becomes available.
| Ticker | Fair Value | Fair Value Upside/Downside | Fair Value Rating | Analyst Price Target | Analyst Target Upside/Downside | Analyst Target Rating | Overall Financial Health | Upcoming Dividend Ex-Date | Dividend Payment Date | Upcoming Dividend | Dividend Yield | Next Earnings Date | P/E Ratio | Price-to-Book Ratio | Price-to-Sales Ratio | Market Cap | Enterprise Value | Total Debt / Total Capital | Free Float / Shares Outstanding | Altman Z-Score | Payout Ratio | Free Cash Flow / Net Income |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
NASDAQ-RPRX
|
$56
|
-2.8% Downside
|
Fair
|
$59.89
|
4.0% Upside
|
Fair
|
Great
|
August 14, 2026
|
September 10, 2026
|
0.94
|
1.6%
|
August 5, 2026
|
30.8x
|
4.8x
|
13.6x
|
32.992 B
|
36.044 B
|
19.9%
|
93.3%
|
2.7
|
46.9%
|
316.1%
|
